Adagene
Yahoo Finance • 12 months ago
Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded
Key Insights The considerable ownership by retail investors in Adagene indicates that they collectively have a greater say in management and business strategy 52% of the business is held by the top 6 shareholders Insiders own 19% of Adage... Full story
Yahoo Finance • last year
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyse... Full story
Yahoo Finance • last year
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene... Full story
Yahoo Finance • 2 years ago
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors - - Tumor shrinkage and prolonged stable... Full story
Yahoo Finance • 2 years ago
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology - - Additional poster reports preclinical... Full story
Yahoo Finance • 2 years ago
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene’s novel anti-CTLA-4 therapies delivered systemically at h... Full story
Yahoo Finance • 2 years ago
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses confirmed in multiple tumor types andco... Full story
Yahoo Finance • 2 years ago
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene’s Co-founder, Chief Ex... Full story
Yahoo Finance • 2 years ago
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with... Full story
Yahoo Finance • 2 years ago
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, t... Full story
Yahoo Finance • 2 years ago
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results include two partial responses as monothe... Full story
Yahoo Finance • 2 years ago
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 acr... Full story
Yahoo Finance • 2 years ago
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report results of ADG126 dose escalation in co... Full story
Yahoo Finance • 2 years ago
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-C... Full story
Yahoo Finance • 3 years ago
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that its board of directors h... Full story
Yahoo Finance • 3 years ago
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combin... Full story
Yahoo Finance • 3 years ago
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates in 2022, including masked anti-CD137 antibody with Fc... Full story
Yahoo Finance • 3 years ago
10 Best Non-Tech Chinese Stocks to Buy Now
In this article, we discuss the 10 best non-tech Chinese stocks to buy now. If you want to read about some more non-tech Chinese stocks, go directly to 5 Best Non-Tech Chinese Stocks to Buy Now. Chinese stocks have been hammered in the pa... Full story
Yahoo Finance • 3 years ago
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater efficacy through higher and more frequent do... Full story
